Diaceutics Beheer

Beheer criteriumcontroles 2/4

De CEO Diaceutics is Ryan Keeling, benoemd in Jan2024, heeft een ambtstermijn van minder dan een jaar. De totale jaarlijkse vergoeding van { bedraagt £ 282.49K, bestaande uit 95.2% salaris en 4.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 3.54% van de aandelen van het bedrijf, ter waarde € 4.16M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.8 jaar en 0.1 jaar.

Belangrijke informatie

Ryan Keeling

Algemeen directeur

UK£282.5k

Totale compensatie

Percentage CEO-salaris	95.2%
Dienstverband CEO	less than a year
Eigendom CEO	3.5%
Management gemiddelde ambtstermijn	less than a year
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Ryan Keeling's beloning veranderd ten opzichte van Diaceutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-UK£3m
Mar 31 2024	n/a	n/a	-UK£2m
Dec 31 2023	UK£282k	UK£269k	-UK£2m
Sep 30 2023	n/a	n/a	-UK£870k
Jun 30 2023	n/a	n/a	UK£6k
Mar 31 2023	n/a	n/a	UK£365k
Dec 31 2022	UK£334k	UK£252k	UK£724k
Sep 30 2022	n/a	n/a	UK£427k
Jun 30 2022	n/a	n/a	UK£129k
Mar 31 2022	n/a	n/a	UK£345k
Dec 31 2021	UK£231k	UK£220k	UK£561k
Sep 30 2021	n/a	n/a	-UK£294k
Jun 30 2021	n/a	n/a	-UK£1m
Mar 31 2021	n/a	n/a	-UK£443k
Dec 31 2020	UK£225k	UK£215k	UK£263k
Sep 30 2020	n/a	n/a	UK£2m
Jun 30 2020	n/a	n/a	UK£3m
Mar 31 2020	n/a	n/a	UK£2m
Dec 31 2019	UK£236k	UK£175k	UK£398k
Sep 30 2019	n/a	n/a	UK£124k
Jun 30 2019	n/a	n/a	-UK£151k
Mar 31 2019	n/a	n/a	UK£241k
Dec 31 2018	UK£78k	n/a	UK£632k

Compensatie versus markt: De totale vergoeding ($USD 354.75K ) Ryan } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 474.54K ).

Compensatie versus inkomsten: De vergoeding van Ryan is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Ryan Keeling (42 yo)

less than a year

Tenure

UK£282,494

Compensatie

Mr. Ryan Keeling serves as Executive Director of Diaceutics PLC, he joined the company in 2006 and serves as Chief Executive Officer since January 1, 2024 and is responsible for the innovation strategy for...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Keeling	Founder & Executive Chairman	less than a year	UK£310.99k	18.65% € 21.9m
Ryan Keeling	CEO & Director	less than a year	UK£282.49k	3.54% € 4.2m
Nicholas Roberts	CFO & Director	2.7yrs	UK£193.05k	0.050% € 58.7k
Ken Ruppel	Vice President of Scientific & Medical Services	less than a year	geen gegevens	geen gegevens
Gillian Shaw	General Counsel	2.8yrs	geen gegevens	geen gegevens
Amie McNiece	Vice President of Marketing	less than a year	geen gegevens	geen gegevens
Marianna Sciortino	Interim VP of Sales	less than a year	geen gegevens	geen gegevens
Sandra Blake	Chief People Officer	less than a year	geen gegevens	geen gegevens
Jordan Clark	Chief Data Officer? & Executive Director	less than a year	geen gegevens	0.83% € 979.8k
Susanne Munksted	Chief Precision Medicine Officer	5.8yrs	geen gegevens	0.30% € 347.3k
Jillian Beggs	Chief Commercial Officer	1.8yrs	geen gegevens	geen gegevens
Madeline Brown	VP & Chief of Staff	less than a year	geen gegevens	geen gegevens

0.8yrs

Gemiddelde duur

42yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 7DC wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Peter Keeling	Founder & Executive Chairman	less than a year	UK£310.99k	18.65% € 21.9m
Ryan Keeling	CEO & Director	no data	UK£282.49k	3.54% € 4.2m
Nicholas Roberts	CFO & Director	2.7yrs	UK£193.05k	0.050% € 58.7k
Jordan Clark	Chief Data Officer? & Executive Director	less than a year	geen gegevens	0.83% € 979.8k
Graham Paterson	Senior Independent Director	1.1yrs	UK£15.00k	0.087% € 102.2k
Cheryl Macdiarmid	Non-Executive Director	less than a year	geen gegevens	geen gegevens

0.08yrs

Gemiddelde duur

47.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 7DC wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.1 jaar), wat duidt op een nieuw bestuur.

Diaceutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Diaceutics PLC Announces the Appointment of Sandra Blake as Chief People Officer

Less than half of directors are independent

Diaceutics plc Announces Board Changes

Diaceutics plc Announces Board Changes

Independent Non-Executive Director recently bought €60k worth of stock

Diaceutics PLC, Annual General Meeting, Jun 24, 2024

Recent updates

Now 20% overvalued

Diaceutics PLC Announces the Appointment of Sandra Blake as Chief People Officer

Less than half of directors are independent

Diaceutics plc Announces Board Changes

First half 2024 earnings released: UK£0.031 loss per share (vs UK£0.018 loss in 1H 2023)

Diaceutics PLC to Report Q2, 2024 Results on Sep 17, 2024

Diaceutics PLC Launches Enhanced Rare-Disease Offering

Diaceutics PLC Announces Launch of PMx

Diaceutics plc Announces Board Changes

Independent Non-Executive Director recently bought €60k worth of stock

Full year 2023 earnings released

Diaceutics PLC Launches Significant Upgrade to Its DXRX Platform

Diaceutics PLC, Annual General Meeting, Jun 24, 2024

New minor risk - Market cap size

Less than half of directors are independent

First half 2023 earnings released: UK£0.018 loss per share (vs UK£0.009 loss in 1H 2022)

New minor risk - Profit margin trend

Diaceutics Announces Executive Changes

Diaceutics PLC Announces Executive Changes, Effective 1 October 2023

Diaceutics plc Launches Daily Alerts for Dxrx Platform

Diaceutics PLC to Report First Half, 2023 Results on Sep 26, 2023

Full year 2022 earnings released: EPS: UK£0.009 (vs UK£0.007 in FY 2021)

Diaceutics PLC Announces Release of Study into Inefficiencies Within Personalised Medicine and Its Impact on Cancer Patients

First half 2022 earnings released: UK£0.009 loss per share (vs UK£0.004 loss in 1H 2021)

Diaceutics PLC to Report First Half, 2022 Results on Sep 27, 2022

Diaceutics PLC Announces New AI and ML Capabilities Enhance DXRX Platform

No independent directors

Executive Officer recently sold €237k worth of stock

Diaceutics PLC Announces Test Signal Launch and Contract Wins

First half 2021 earnings released: UK£0.004 loss per share (vs UK£0.015 profit in 1H 2020)

Diaceutics PLC Provides Earnings Guidance for the Year 2021

Chief Commercial Officer recently sold €73k worth of stock

CFO & Executive Director recently sold €284k worth of stock

Full year 2020 earnings released

Diaceutics PLC Appoints Nikita Lynn as Vice President of Finance

Investor sentiment improved over the past week

Diaceutics PLC to Report Fiscal Year 2020 Results on Mar 15, 2021

Investor sentiment improved over the past week

Diaceutics PLC Announces the Resignation of Julie Goonewardene as Non-Executive Chair, with Effect from December 31, 2020

Diaceutics and Alva10 Partner to Deliver Value-Based Test Reimbursement Model for US Payers, Pharma and Testing Providers Via Dxrx Platform

Diaceutics PLC Launches Diagnostic Network for Precision Medicine to Solve Global Cancer Testing Issues

Market pulls back on stock over the past week

Diaceutics PLC Partners with Global EQA Providers to Implement Best-In-Class Testing Standards

New 90-day high - €2.12

Diaceutics PLC announced that it has received £4 million in funding from SVB Silicon Valley Bank, Investment Arm

New 90-day high - €2.04

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd